Siegfried announces the acquisition of a 95% stake in DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and gene therapies
Siegfried broke ground to build a new global R&D Center for Drug Substances at its site in Evionnaz, Switzerland
Siegfried Holding AG’s shareholders approved all proposals of the Board of Directors. They approved the increase in the distribution to shareholders in the form of repayment from share capital from 3.20 to 3.40 Swiss francs per registered share.
Siegfried inaugurates a state-of-the-art Development Center for Drug Products in Barcelona, including dedicated facilities for highly potent Drug Products
Net sales up to CHF 1.229 billion (+15.6% increase versus prior year in local currencies). Core EBITDA of CHF 272.5 million (prior year CHF 207.2 million) at an expanded margin of 22.2% (prior year 18.8%)
Christian Dowdeswell will become Chief Business Officer Drug Substances and member of Siegfried’s Executive Committee. Marianne Späne will continue to lead the business development and sales activities in the area of finished dosage forms as Chief Business Officer Drug Products.